Pure Biologics (STU:PQB) Other Current Payables: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PQB Pure Biologics SA STU:PQB
21 GF Score
Price €0.40
! 2 Warning Signs
View Full Analysis

What is Pure Biologics Other Current Payables?

Pure Biologics STU:PQB +0.50% 21 Other Current Payables is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:PQB with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Pure Biologics's Other Current Payables for the quarter that ended in Mar. 2026 was €0.00 Mil.

Pure Biologics's quarterly Other Current Payables declined from Sep. 2025 (€0.01 Mil) to Dec. 2025 (€0.00 Mil) but then stayed the same from Dec. 2025 (€0.00 Mil) to Mar. 2026 (€0.00 Mil).

Pure Biologics's annual Other Current Payables declined from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€-0.00 Mil) but then increased from Dec. 2024 (€-0.00 Mil) to Dec. 2025 (€0.00 Mil).

Pure Biologics Other Current Payables Related Terms

Pure Biologics Other Current Payables Historical Data

* Premium members only.

The historical data trend for Pure Biologics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pure Biologics Other Current Payables Chart

Pure Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 0.00

Pure Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.01 0.00 0.00
STU:PQB
21GF Score
Pure Biologics SA STU:PQB
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pure Biologics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €0.00 Mil mean?
Pure Biologics (STU:PQB) has a Other Current Payables of €0.00 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Pure Biologics and its competitors.
Is Pure Biologics' Other Current Payables too high?
Pure Biologics' current Other Current Payables is €0.00 Mil. Overall, Pure Biologics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Pure Biologics' Other Current Payables compare to VRTX and REGN?
Pure Biologics' Other Current Payables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Pure Biologics and its competitors. Pure Biologics's current Other Current Payables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pure Biologics stock overvalued right now?
Pure Biologics (STU:PQB) has a current Other Current Payables of €0.00 Mil. The current Other Current Payables is €0.00 Mil. Pure Biologics' overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Pure Biologics (STU:PQB), the current Other Current Payables is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pure Biologics Business Description

Other Exchanges PUR:Poland
Address ul. Dunska 11, Wroclaw, POL, 54-427
Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects.
21GF Score

Get the complete analysis for STU:PQB

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.40
Price